El-Zohery Nora T, Shalaby Yousra R, Kasem Ayman I, Mostafa Rasha R
Pathology Department, Faculty of Medicine, Cairo University, Egypt.
Department of Anatomic Pathology, Faculty of Medicine, Kasr Al-Ainy, Cairo University, Cairo, Egypt.
Asian Pac J Cancer Prev. 2025 Mar 1;26(3):889-897. doi: 10.31557/APJCP.2025.26.3.889.
Egypt has a significantly higher prevalence of cancer bladder than the rest of the world. CD-14 antigen is involved in Toll-like receptor-mediated signaling pathways in inflammatory tumor microenvironment which promote tumor development and proliferation. There have been few studies on CD14 antigen effect on urothelial carcinoma of the urinary bladder. This study aimed to evaluate the role of CD14 in prognosis of uurothelial carcinoma of the urinary bladder and its association with the tumor progression.
This retrospective cross-sectional study included fifty-one cases of urothelial carcinoma obtained either by cystoscopic biopsies or radical cystectomies. They were immunohistochemically stained using anti- CD14 antibody. Statistical correlations between CD14 expression and available clinicopathological data were done.
Positive immunoexpression of CD14 was noted in 84.3% of all cases, showing scores 1, 2 & 3 in 9.8%, 29.4%, and 45.1% of cases, respectively. While negative immunoexpression was noted in 15.7% of cases and was scored as 0. A statistically significant correlation was noticed between CD14 immunohistochemical expression and each of the tumor grade, pathological tumor stage, status of muscle invasion, and pathological lymph node stage (P value=0.045, 0.030, 0.001, and 0.008 respectively). However, no statistically significant correlation was noted between CD14 immunohistochemical expression and each of the two-year survival rates in radical cystectomy cases and the mortality rate after exclusion of the postoperative complications (P value = 0.114 & 0.156 respectively).
The intensity of CD14 expression was weak and even lost in high-grade and late-stage urothelial bladder carcinoma cases, while low-grade urothelial carcinoma cases showed CD14 overexpression. Accordingly, the significance of therapeutic approaches targeting CD14 in high-grade and late-stage urothelial bladder carcinoma shall be questionable.
埃及膀胱癌的患病率显著高于世界其他地区。CD - 14抗原参与炎症性肿瘤微环境中Toll样受体介导的信号通路，促进肿瘤发展和增殖。关于CD14抗原对膀胱尿路上皮癌的影响，此前研究较少。本研究旨在评估CD14在膀胱尿路上皮癌预后中的作用及其与肿瘤进展的关系。
本回顾性横断面研究纳入了51例通过膀胱镜活检或根治性膀胱切除术获取的尿路上皮癌病例。使用抗CD14抗体对其进行免疫组织化学染色。对CD14表达与现有的临床病理数据进行统计学相关性分析。
所有病例中84.3%观察到CD14免疫表达阳性，其中9.8%、29.4%和45.1%的病例分别显示评分为1、2和3。15.7%的病例观察到免疫表达阴性，评分为0。CD14免疫组织化学表达与肿瘤分级、病理肿瘤分期、肌肉浸润状态和病理淋巴结分期均存在统计学显著相关性（P值分别为0.045、0.030、0.001和0.008）。然而，在根治性膀胱切除病例中，CD14免疫组织化学表达与两年生存率以及排除术后并发症后的死亡率之间均未观察到统计学显著相关性（P值分别为0.114和0.156）。
在高级别和晚期膀胱尿路上皮癌病例中，CD14表达强度较弱甚至缺失，而低级别尿路上皮癌病例显示CD14过表达。因此，针对高级别和晚期膀胱尿路上皮癌靶向CD14的治疗方法的意义值得怀疑。
